trial

Brexpiprazole in Patients With Acute Schizophrenia

NCTId NCT01810380
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 468 (actual)
Sponsored by H. Lundbeck A/S
Primary completion 2014-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
468 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2013-03
Primary completion
2014-12
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Brexpiprazole (Rexulti)Quetiapine

Sponsors

H. Lundbeck A/SLead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.Collaborator

Sites

1 total
Escondido, United States

Linked catalysts

1
Brexpiprazole in Patients With Acute Schizophrenia — primary completion2014-12

Facts & assertions

4 sourced
Enrollment
468
Phase
PHASE3
Primary Completion Date
2014-12
Status
COMPLETED
relationships
The graph out of here
drug
Brexpiprazole (Rexulti)
drug
Quetiapine
drug
lead_sponsor
H. Lundbeck A/S
company
collaborator
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication